Provide the API as well as Trametinib（CAS No.:871700-17-3）.
[Indication]
1. For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation.
2. In combination with trametinib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation.
3. In combination with trametinib for the adjuvant treatment of patients with Stage III melanoma with BRAF V600E or V600K mutation who have undergone complete resection.
4. In combination with trametinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation.
5. In combination with trametinib for the treatment of patients with locally recurrent or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation.
